List of Excipients in Branded Drug BASIC CARE MIGRAINE RELIEF

« Back to Dashboard

Generic Drugs Containing BASIC CARE MIGRAINE RELIEF

Company	Ingredient	NDC	Excipient
L Perrigo Company	acetaminophen, aspirin, caffeine	0113-7374	CARNAUBA WAX
L Perrigo Company	acetaminophen, aspirin, caffeine	0113-7374	CELLULOSE, MICROCRYSTALLINE
L Perrigo Company	acetaminophen, aspirin, caffeine	0113-7374	CROSPOVIDONE
L Perrigo Company	acetaminophen, aspirin, caffeine	0113-7374	FD&C BLUE NO. 1
L Perrigo Company	acetaminophen, aspirin, caffeine	0113-7374	HYPROMELLOSES
L Perrigo Company	acetaminophen, aspirin, caffeine	0113-7374	POVIDONE
L Perrigo Company	acetaminophen, aspirin, caffeine	0113-7374	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in BASIC CARE MIGRAINE RELIEF?

# Of NDCs	Excipient
3	CARNAUBA WAX
3	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
1	D&C YELLOW NO. 10
3	FD&C BLUE NO. 1
1	FERROSOFERRIC OXIDE
1	GELATIN

Basic Care Migraine Relief Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Basic Care Migraine Relief is an OTC combination analgesic built around acetaminophen, aspirin, and caffeine. Its commercial opportunity is primarily a low-cost, private-label alternative to Excedrin Migraine, with differentiation available through tablet performance, packaging, tolerability, and retail-channel execution rather than through a novel active ingredient or strong composition-of-matter patent estate.

What is the formulation of Basic Care Migraine Relief?

Basic Care Migraine Relief uses the standard OTC migraine combination:

Active ingredient	Strength per tablet	Primary role
Acetaminophen	250 mg	Analgesic
Aspirin	250 mg	Analgesic and anti-inflammatory NSAID
Caffeine	65 mg	Analgesic adjuvant

The active-ingredient profile is consistent with the FDA-recognized combination used in Excedrin Migraine and other aspirin-acetaminophen-caffeine products. FDA labeling identifies the combination as an OTC migraine treatment for adults and children age 12 and older, subject to warning restrictions for acetaminophen, aspirin, caffeine, stomach bleeding, liver toxicity, and medication-overuse headache.[1]

Basic Care is an Amazon private-label brand. The product competes on price, availability, and similarity to branded combination analgesics. The product is not a biologic and does not require biosimilar development. Its regulatory and commercial profile is closer to a store-brand OTC tablet than to a prescription drug with a conventional Orange Book patent lifecycle.

What excipients are used in Basic Care Migraine Relief?

Public product labeling identifies a conventional immediate-release tablet platform. Inactive ingredients reported for this type of product include tablet fillers, binders, disintegrants, glidants, lubricants, and coating materials. The exact excipient list can vary by manufacturer, contract manufacturing site, tablet presentation, and packaging configuration.

A representative excipient architecture is:

Excipient class	Likely materials	Commercial function
Diluent	Microcrystalline cellulose	Tablet mass, compression, mechanical strength
Binder	Povidone, pregelatinized starch	Granule and tablet cohesion
Disintegrant	Crospovidone, pregelatinized starch	Rapid breakup after ingestion
Glidant	Colloidal silicon dioxide	Powder flow and die filling
Lubricant	Stearic acid or a comparable lubricant	Ejection from tablet tooling
Surfactant	Sodium lauryl sulfate	Wetting and dissolution support
Film former	Hypromellose	Coating integrity and swallowability
Opacifier or colorant	Titanium dioxide or other approved colorants	Appearance and light protection
Anti-adherent	Talc, where used	Reduced sticking during compression

The main formulation challenge is not chemical novelty. It is balancing rapid disintegration with adequate tablet hardness, low friability, acceptable taste, and stable dissolution for three chemically different actives.

How do the active ingredients affect excipient selection?

Acetaminophen, aspirin, and caffeine have different formulation behaviors:

• Aspirin is sensitive to moisture and can hydrolyze to salicylic acid and acetic acid.
• Acetaminophen can create high-dose tablet mass and may require careful compression control.
• Caffeine can migrate, segregate, or contribute to powder-flow problems if particle-size distributions are mismatched.
• The combination can produce a bitter and acidic taste profile.
• Aspirin and caffeine can increase gastric irritation concerns, which limits the value of aggressive disintegration or high local dissolution rates if the product is positioned as a gentler formulation.

Moisture management is the central excipient and packaging issue. Low-water-activity excipients, controlled granulation, low-residual-moisture processing, and high-barrier packaging can reduce aspirin degradation. Excessive use of hygroscopic binders or poorly controlled aqueous granulation can increase stability risk.

What excipient strategy offers the strongest commercial advantage?

The highest-value strategy is an immediate-release, low-moisture formulation optimized for rapid and reproducible dissolution without adding unnecessary excipients.

Recommended platform formulation

A commercially efficient platform would use:

1. Microcrystalline cellulose and pregelatinized starch for compression and binding.
2. Crospovidone for rapid disintegration.
3. A controlled level of colloidal silicon dioxide for flow.
4. A low-level hydrophobic lubricant to avoid delayed dissolution.
5. Sodium lauryl sulfate or another compatible wetting agent only where dissolution data justify its use.
6. A thin hypromellose film coat to improve swallowability and protect the tablet.
7. High-barrier aluminum-aluminum blister packaging or a tightly controlled HDPE bottle with desiccant.

The formulation should avoid excipient complexity that does not produce a measurable benefit. Every additional excipient increases supplier qualification, analytical testing, labeling review, and change-control obligations.

Which excipient upgrades could create premium products?

Several modifications could support differentiated SKUs:

Product concept	Excipient or dosage-form strategy	Commercial benefit
Rapid-release caplet	Crospovidone, optimized porosity, low-lubricant formulation	Faster onset positioning
Easy-swallow tablet	Thin film coat, capsule-shaped caplet, reduced tablet thickness	Better adherence and consumer acceptance
Gentle-on-stomach version	Delayed-release aspirin or separate-release architecture	Potential tolerability positioning, but higher technical and regulatory complexity
Caffeine-controlled version	Modified-release matrix or separate immediate-release caffeine layer	Differentiation, but not aligned with the standard migraine combination
Travel pack	Moisture-barrier unit-dose blister	Portability and stability
Sugar-free chewable	Mannitol, xylitol, sucralose, flavor system	New use occasion, but major taste and stability challenges
Powder or effervescent product	Solubilizing excipients, acid-base system, flavoring	Fast preparation and consumer differentiation
Pediatric-adjacent product	Lower-strength actives and age-specific labeling	Significant safety and regulatory constraints; not a simple line extension

The most practical opportunities are rapid-release caplets, easy-swallow tablets, and unit-dose blister packs. Delayed-release and effervescent versions require substantially more development work and may introduce new safety, stability, and labeling issues.

What formulations are protected by patents?

The core aspirin-acetaminophen-caffeine combination is mature and widely marketed. Basic Care Migraine Relief is unlikely to depend on a meaningful product-specific composition-of-matter patent estate. The principal protection is more likely to come from:

• Brand and trade dress rights.
• Manufacturer know-how.
• Manufacturing specifications.
• Supplier agreements.
• Packaging design.
• Product-quality controls.
• Potentially narrow formulation or process patents held by third parties.

The standard OTC actives are covered by the FDA OTC monograph framework rather than by a new chemical entity exclusivity model. The applicable analgesic and antipyretic requirements are located in 21 C.F.R. Part 343.[2]

A specific excipient combination could be patentable only if it demonstrated a defensible technical effect, such as improved aspirin stability, faster dissolution under relevant conditions, reduced degradation, or a clinically meaningful tolerability benefit. Merely substituting one conventional filler or disintegrant for another would generally provide weak patent differentiation.

What is the Orange Book status of Basic Care Migraine Relief?

Basic Care Migraine Relief is generally positioned as an OTC monograph product, not as a prescription NDA product with standard Orange Book listings. As a result:

Exclusivity or patent mechanism	Relevance to Basic Care
Orange Book-listed patents	Generally not the primary protection mechanism
Paragraph IV certification	Usually not applicable to a monograph OTC product
New chemical entity exclusivity	Not applicable
Three-year clinical investigation exclusivity	Not applicable absent an applicable NDA
Five-year pediatric exclusivity	Not applicable to the standard OTC monograph pathway
OTC monograph compliance	Primary regulatory route
Trademark and trade dress	Commercially relevant
Formulation and process know-how	Potentially relevant but generally confidential

FDA’s OTC monograph system allows compliant products to be marketed without the same product-specific approval structure used for prescription drugs.[3] A manufacturer pursuing a materially different dosage form, indication, active combination, or delivery system may need an NDA or another FDA pathway rather than relying solely on the monograph.

When does Basic Care Migraine Relief lose exclusivity?

Basic Care Migraine Relief does not have a conventional drug exclusivity expiration date comparable to a patented prescription medicine. The active ingredients and therapeutic category are mature. Competitive entry depends on compliance with FDA OTC requirements, manufacturing economics, retailer access, and brand positioning.

The practical loss of exclusivity occurred when multiple manufacturers began marketing equivalent aspirin-acetaminophen-caffeine products. The relevant commercial question is not when a patent expires, but whether a new entrant can meet:

• OTC monograph requirements.
• Current good manufacturing practice requirements.
• Stability specifications.
• Labeling and warning requirements.
• Product-quality and dissolution targets.
• Retailer and marketplace qualification standards.

Are there Paragraph IV challenges or generic entry risks?

A conventional Paragraph IV challenge is not the main entry route for a standard Basic Care OTC product. Generic and private-label entrants can compete by developing their own compliant OTC products.

Generic entry risk is high because:

• The actives are inexpensive and widely available.
• The formulation technology is conventional.
• Contract manufacturers can produce the tablets at scale.
• Consumers recognize the therapeutic category.
• Retailers can substitute one supplier for another.
• Product-level differentiation is limited.

The principal barriers are execution barriers rather than patent barriers. These include aspirin stability, dissolution consistency, tablet segregation, packaging performance, supply continuity, and compliance history.

What patent litigation affects Basic Care Migraine Relief?

There is no widely identified litigation framework surrounding Basic Care Migraine Relief comparable to the patent disputes involving branded prescription drugs. Litigation risk is more likely to arise from:

1. Trademark or trade dress claims involving Excedrin or other branded products.
2. Advertising claims about speed, effectiveness, or superiority.
3. Product liability claims involving liver injury, gastrointestinal bleeding, or dosing errors.
4. Manufacturing or quality disputes.
5. Private-label supply and indemnification disputes.
6. Packaging or child-resistant closure compliance.

For a new entrant, freedom-to-operate review should focus on differentiated dosage forms, release profiles, tablet geometry, coating systems, and packaging patents rather than on the mature active ingredients.

How strong is the patent estate for Basic Care Migraine Relief?

The patent estate is weak for the standard tablet concept and potentially moderate for a differentiated delivery platform.

Asset type	Estimated strategic strength
Aspirin-acetaminophen-caffeine combination	Low
Conventional immediate-release tablet	Low
Standard excipient substitution	Low
Moisture-control process	Low to moderate, often better protected as know-how
Specific rapid-dissolution architecture	Moderate if supported by comparative data
Delayed-release or multilayer tablet	Moderate to strong if claims are narrow and technically validated
Specialized blister packaging	Moderate, depending on structure and claims
Brand, trade dress, and retailer placement	Moderate commercial value
Manufacturing know-how	Moderate operational value, limited public enforceability

A patent strategy should target measurable performance. Useful claim themes could include aspirin degradation control, dissolution uniformity across all three actives, low-moisture granulation, multilayer release, or a packaging-formulation combination that extends shelf life.

What FDA regulatory status applies to the product?

The product is an OTC analgesic and migraine product. The relevant compliance areas include:

• Permitted active ingredients and strengths.
• Required Drug Facts labeling.
• Contraindications and warnings.
• Directions for adults and children 12 years and older.
• Acetaminophen maximum daily exposure.
• Aspirin gastrointestinal bleeding warnings.
• Caffeine disclosure and usage warnings.
• Good manufacturing practice.
• Stability and expiration dating.
• Complaint handling and adverse-event reporting.

FDA has repeatedly emphasized the risk of unintentional acetaminophen overdose when consumers use more than one acetaminophen-containing product.[4] The packaging and label should therefore make the 250 mg acetaminophen content conspicuous and should discourage concurrent use with other acetaminophen products.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have several entry points beyond commodity volume:

High-barrier packaging

Aspirin’s moisture sensitivity supports premium demand for:

• Aluminum-aluminum blisters.
• High-density polyethylene bottles with desiccants.
• Induction-sealed closures.
• Low-moisture unit-dose systems.
• Packaging that supports travel and adherence.

Packaging can create more defensible value than a conventional filler because it directly affects shelf life, product quality, and consumer convenience.

Functional disintegrants and binders

Suppliers can position crospovidone, modified starch, silicified microcrystalline cellulose, and co-processed excipients around:

• Faster disintegration.
• Lower compression force.
• Better tablet robustness.
• Reduced friability.
• Improved manufacturing throughput.
• Lower lubricant sensitivity.

The strongest sales case requires comparative data using the actual three-active formulation, not general excipient performance claims.

Taste and swallowability systems

Taste masking has value for chewables, orally disintegrating tablets, and pediatric-adjacent products. The commercial constraint is that aspirin and acetaminophen create a difficult taste profile, while caffeine adds bitterness. Flavor systems, polymer coatings, ion-exchange resins, and multiparticulate approaches can help, but these increase formulation cost.

Stability-enabling systems

Excipient suppliers can support:

• Low-moisture processing.
• Oxygen and moisture scavenging.
• pH control where compatible with the dosage form.
• Improved powder flow.
• Reduced segregation among active ingredients.
• Extended shelf life under accelerated and long-term conditions.

Stability data are likely to have more commercial value than a generic “clean label” claim.

How does Basic Care compare with Excedrin Migraine?

Factor	Basic Care Migraine Relief	Excedrin Migraine
Active combination	Aspirin 250 mg, acetaminophen 250 mg, caffeine 65 mg	Same standard combination
Primary positioning	Value and private label	Branded recognition
Patent dependence	Limited	Limited for mature combination
Retail advantage	Amazon and value channels	Broad pharmacy and mass retail distribution
Excipient differentiation	Potentially modest	Primarily product consistency and brand experience
Consumer price	Typically lower	Typically higher
Competitive threat	Other store brands and generics	Private-label substitution
Key moat	Channel placement and price	Brand trust, distribution, and marketing

The most credible competitive strategy is a lower-cost product with equivalent tablet performance, stronger moisture protection, and packaging optimized for repeat use.

What generic launch scenarios exist?

Three launch scenarios are commercially realistic:

Low-cost equivalent tablet

This approach uses a conventional immediate-release formulation and competes on unit economics. It has the lowest development risk but also the lowest differentiation.

Premium rapid-release caplet

This approach uses a validated disintegration and dissolution advantage, improved swallowability, and unit-dose packaging. It can support a higher price if the claim is substantiated and clearly communicated.

New delivery format

A chewable, effervescent, powder, or multilayer product could create stronger differentiation. The development cost, taste burden, stability risk, and regulatory review burden are materially higher.

The most attractive near-term opportunity is the premium rapid-release caplet with high-barrier packaging. It preserves the familiar active combination while creating measurable product attributes.

What geographic opportunities exist?

The active combination is familiar in the United States and other markets, but regulatory treatment varies by country. A commercial expansion program would need country-specific review of:

• OTC versus prescription classification.
• Permitted aspirin and acetaminophen strengths.
• Caffeine limits.
• Required warnings.
• Label language.
• Product registration.
• Advertising restrictions.
• Import and manufacturing requirements.

The United States offers the clearest private-label opportunity because of the established OTC analgesic market and retailer familiarity. International expansion may require reformulation, especially where aspirin use, caffeine content, or combination analgesics receive tighter restrictions.

Key Takeaways

• Basic Care Migraine Relief is a mature OTC aspirin-acetaminophen-caffeine combination.
• The standard product has limited patent and exclusivity protection.
• The strongest formulation priorities are aspirin moisture control, rapid disintegration, tablet robustness, and acceptable swallowability.
• High-barrier packaging may create more commercial value than a novel conventional excipient blend.
• Rapid-release caplets, easy-swallow tablets, and unit-dose blister packs are the most practical differentiated products.
• Paragraph IV litigation is generally not the central competitive issue because OTC monograph entry does not depend on challenging an Orange Book-listed patent.
• The principal barriers are manufacturing quality, stability, labeling compliance, retail economics, and supply reliability.
• Excipient suppliers should support claims with data from the actual three-active formulation.
• A differentiated formulation patent would need a measurable technical effect, not a routine excipient substitution.
• Excedrin Migraine remains the main branded benchmark, while private labels compete through price and channel access.

FAQs About Basic Care Migraine Relief Excipient and Commercial Strategy

Can Basic Care Migraine Relief be made as an effervescent product?

Yes, but the product would require a new acid-base system, moisture-controlled manufacturing, taste masking, and packaging capable of preventing premature reaction. The regulatory pathway and stability burden would be higher than for an immediate-release tablet.

Is aspirin stability the main shelf-life risk?

Aspirin degradation is a major risk because moisture can promote hydrolysis. Packaging, residual moisture, granulation conditions, and excipient water activity should be evaluated together.

Can a new excipient combination obtain a patent?

Potentially, but patent strength would depend on unexpected performance, such as materially improved stability or dissolution. Routine substitution of microcrystalline cellulose, starch, or crospovidone would generally provide weak patent scope.

Does the product require an ANDA?

A standard OTC monograph product generally does not require an ANDA solely because it is equivalent to another OTC product. A materially different product or unapproved claim may require an NDA or another FDA authorization pathway.

What is the best premium positioning for a private-label migraine product?

A rapid-release, easy-swallow caplet in moisture-protective unit-dose packaging offers the clearest premium position without changing the established active combination.

References

1. U.S. Food and Drug Administration. (2024). OTC drug facts label: Aspirin, acetaminophen, and caffeine migraine relief products. FDA. https://www.fda.gov/drugs
2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343
3. U.S. Food and Drug Administration. (2023). Over-the-counter drug review: Monograph system. FDA. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines
4. U.S. Food and Drug Administration. (2023). Acetaminophen and liver injury: Current safety information. FDA. https://www.fda.gov/drugs/information-drug-class/acetaminophen-information-pa​​atient-safety